Skip to main content
Top
Published in: CEN Case Reports 1/2021

01-02-2021 | Computed Tomography | Case Report

Concurrent minimal change disease and retroperitoneal liposarcoma successfully treated by tumor resection and steroid therapy

Authors: Yuki Yasui, Ryoko Shibata, Natsumi Morita, Naoko Himuro, Aki Hamauchi, Maho Watanabe, Kenji Ito, Tetsuhiko Yasuno, Yasuhiro Abe, Katsuhisa Miyake, Fumihiro Yoshimura, Makoto Hamsaki, Satoshi Hisano, Kosuke Masutani, Hitoshi Nakashima

Published in: CEN Case Reports | Issue 1/2021

Login to get access

Abstract

A 54-year-old Japanese woman developed simultaneous abdominal distension and bilateral leg edema. Her medical history and results of periodic medical check-up were unremarkable. Blood tests revealed severe hypoproteinemia and acute kidney injury, and urinalysis revealed 4+ proteinuria and 2+ hematuria. Abdominal computed tomography revealed a large intra-abdominal mass with fat tissue density. She underwent emergency tumor excision, splenectomy, and distal pancreatectomy. However, hypoproteinemia and acute kidney injury worsened. Therefore, she was transferred to the nephrology division for confirmation of diagnosis and for treatment of acute kidney injury and nephrotic syndrome. We conducted percutaneous kidney biopsy and diagnosed minimal change disease (MCD). Intravenous prednisolone was started, and heavy proteinuria and systemic edema were gradually alleviated. She achieved complete remission 2 months later, and oral prednisolone was tapered. Histopathological diagnosis of abdominal tumor was dedifferentiated liposarcoma of retroperitoneal origin. Immunohistochemical staining revealed strong expression of vascular endothelial growth factor in the tumor cells in the dedifferentiated component. Currently, her clinical course is stable without recurrence of liposarcoma and nephrotic syndrome. MCD develops in patients with Hodgkin’s lymphoma, solid organ cancers, hematological malignancies, and thymoma, whereas concurrent MCD and liposarcoma are rare. Remission of nephrotic syndrome and normalized kidney function induced by steroid therapy are important for better management of patients with malignancy.
Literature
1.
go back to reference Bacchetta J, Juillard L, Cochat P, Droz JP. Paraneoplastic glomerular diseases and malignancies. Crit Rev Oncol Hematol. 2009;70:39–58.CrossRef Bacchetta J, Juillard L, Cochat P, Droz JP. Paraneoplastic glomerular diseases and malignancies. Crit Rev Oncol Hematol. 2009;70:39–58.CrossRef
2.
go back to reference Lien YHH, Lai LW. Pathogenesis diagnosis and management of paraneoplastic glomerulonephritis. Nat Rev Nephrol. 2011;7:85–95.CrossRef Lien YHH, Lai LW. Pathogenesis diagnosis and management of paraneoplastic glomerulonephritis. Nat Rev Nephrol. 2011;7:85–95.CrossRef
3.
go back to reference Sherman JL, Liu EY, Ozao-Choy J, Winston JA, Lee J, Dikman SH, et al. Paraneoplastic glomerulopathy secondary to retroperitoneal sarcoma: a case report. J Surg Oncol. 2010;102:704–5.CrossRef Sherman JL, Liu EY, Ozao-Choy J, Winston JA, Lee J, Dikman SH, et al. Paraneoplastic glomerulopathy secondary to retroperitoneal sarcoma: a case report. J Surg Oncol. 2010;102:704–5.CrossRef
4.
go back to reference Arnal Babiloni M, Cabadés O’Callaghan F, Cortés V, Polo JA. Membranous glomerulonephritis secondary to retroperitoneal sarcoma. Med Clin. 1997;109:356–7 (in Spanish). Arnal Babiloni M, Cabadés O’Callaghan F, Cortés V, Polo JA. Membranous glomerulonephritis secondary to retroperitoneal sarcoma. Med Clin. 1997;109:356–7 (in Spanish).
5.
go back to reference Lai MY, Yang CY, Yang WC, Chang YH, Shen SH, Pan CC, et al. Giant bilateral perinephric tumour and overt proteinuria. Nephrol Dial Transplant. 2007;22:2089–90.CrossRef Lai MY, Yang CY, Yang WC, Chang YH, Shen SH, Pan CC, et al. Giant bilateral perinephric tumour and overt proteinuria. Nephrol Dial Transplant. 2007;22:2089–90.CrossRef
6.
go back to reference Liles JS, Tzeng CWD, Short JJ, Kulesza P, Heslin MJ. Retroperitoneal and intra-abdominal sarcoma. Curr Probl Surg. 2009;46:445–503.CrossRef Liles JS, Tzeng CWD, Short JJ, Kulesza P, Heslin MJ. Retroperitoneal and intra-abdominal sarcoma. Curr Probl Surg. 2009;46:445–503.CrossRef
8.
go back to reference Dalal KMM. Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg. 2006;244:381–91.PubMedPubMedCentral Dalal KMM. Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg. 2006;244:381–91.PubMedPubMedCentral
9.
go back to reference Matthyssens LE, Creytens D, Ceelen WP. Retroperitoneal liposarcoma: current insights in diagnosis and treatment. Front Surg. 2015;2:4.CrossRef Matthyssens LE, Creytens D, Ceelen WP. Retroperitoneal liposarcoma: current insights in diagnosis and treatment. Front Surg. 2015;2:4.CrossRef
10.
go back to reference Kofman T, Zhang SY, Copie-Bergman C, Moktefi A, Raimbourg Q, Francois H, et al. Minimal change nephrotic syndrome associated with non-Hodgkin lymphoid disorders. A retrospective study of 18 cases. Medicine. 2014;93:350–8.CrossRef Kofman T, Zhang SY, Copie-Bergman C, Moktefi A, Raimbourg Q, Francois H, et al. Minimal change nephrotic syndrome associated with non-Hodgkin lymphoid disorders. A retrospective study of 18 cases. Medicine. 2014;93:350–8.CrossRef
11.
go back to reference Karras A, de Montpreville V, Fakhouri F, Grünfeld JP, Lesavre P, for the Groupe d’Etudes des Néphropathies Associées aux Thymomes. Renal and thymic pathology in thymoma-associated nephropathy: report of 21 cases and review of the literature. Nephrol Dial Transplant. 2005;20:1075–82.CrossRef Karras A, de Montpreville V, Fakhouri F, Grünfeld JP, Lesavre P, for the Groupe d’Etudes des Néphropathies Associées aux Thymomes. Renal and thymic pathology in thymoma-associated nephropathy: report of 21 cases and review of the literature. Nephrol Dial Transplant. 2005;20:1075–82.CrossRef
12.
go back to reference Taniguchi K, Fujioka H, Torashima Y, Yamaguchi J, Izawa K, Kanematsu T. Rectal cancer with paraneoplastic nephropathy: association of vascular endothelial growth factor. Dig Surg. 2004;21:455–7.CrossRef Taniguchi K, Fujioka H, Torashima Y, Yamaguchi J, Izawa K, Kanematsu T. Rectal cancer with paraneoplastic nephropathy: association of vascular endothelial growth factor. Dig Surg. 2004;21:455–7.CrossRef
13.
go back to reference Mentzel T, Brown LF, Dvorak HF, Kuhnen C, Stiller KJ, Katenkamp D, et al. The association between tumour progression and vascularity in myxofibrosarcoma and myxoid/round cell liposarcoma. Virch Arch. 2001;438:13–22.CrossRef Mentzel T, Brown LF, Dvorak HF, Kuhnen C, Stiller KJ, Katenkamp D, et al. The association between tumour progression and vascularity in myxofibrosarcoma and myxoid/round cell liposarcoma. Virch Arch. 2001;438:13–22.CrossRef
14.
go back to reference Dong M, Bi J, Liu X, Wang B, Wang J, Wang B, Wang J. Significant partial response of metastatic intra-abdominal and pelvic round cell liposarcoma to a small-molecule VEGFR-2 tyrosine kinase inhibitor apatinib: a case report. Medicine. 2016;95:e4368.CrossRef Dong M, Bi J, Liu X, Wang B, Wang J, Wang B, Wang J. Significant partial response of metastatic intra-abdominal and pelvic round cell liposarcoma to a small-molecule VEGFR-2 tyrosine kinase inhibitor apatinib: a case report. Medicine. 2016;95:e4368.CrossRef
Metadata
Title
Concurrent minimal change disease and retroperitoneal liposarcoma successfully treated by tumor resection and steroid therapy
Authors
Yuki Yasui
Ryoko Shibata
Natsumi Morita
Naoko Himuro
Aki Hamauchi
Maho Watanabe
Kenji Ito
Tetsuhiko Yasuno
Yasuhiro Abe
Katsuhisa Miyake
Fumihiro Yoshimura
Makoto Hamsaki
Satoshi Hisano
Kosuke Masutani
Hitoshi Nakashima
Publication date
01-02-2021
Publisher
Springer Singapore
Published in
CEN Case Reports / Issue 1/2021
Electronic ISSN: 2192-4449
DOI
https://doi.org/10.1007/s13730-020-00528-z

Other articles of this Issue 1/2021

CEN Case Reports 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine